ArticleBrazilian oral research2025
Oral manifestations of COVID-19 vaccinated individuals, post-infection, and different variants: a Brazilian population study.
Article in Brazilian oral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cross-sectional study aims to investigate the prevalence of oral manifestations in a sample of the Brazilian population with COVID-19. Adults diagnosed with COVID-19 through real-time PCR/serological tests were invited to participate. The online questionnaires were distributed at different times to analyze and compare SARS-CoV-2 variants considering the period of prevalence of these variants in Brazil. A total of 846 participants were included, of whom 539 were diagnosed before the Omicron variant. In total, 47.28% were vaccinated with at least two doses. The prevalence of oral manifestations was 52.6% (95%CI: 49.23-55.95), and the most common manifestations included taste disorder (38.06%; 95%CI: 34.85-41.38), xerostomia (17.61%; 95%CI: 15.19-20.32), and halitosis (11.58%; 95%CI: 9.59-13.92). The prevalence of persistent symptoms in post-COVID-19 was 12.1% (95%CI: 10.0-14.4) for taste disorder and 5.4% (95%CI: 4.1-7.1) for xerostomia. A significant association was found between females and persistent taste disorder (p = 0.0084) and oral manifestation and depression/anxiety (OR = 1.855, 95%CI: 1.267-2.717, p = 0.002), worse oral hygiene (OR = 1.729, 95%CI: 1.189-2.516, p = 0.004), and medication use (OR = 1.630, 95%CI: 1.123-2.367, p = 0.010) (p < 0.0001). In the Alpha, Beta, Gamma, and Delta variants, compared with the Omicron variant, taste disorder and xerostomia were less present when toothbrushing habits remained unchanged or improved (p < 0.0001). Oral manifestations in patients with COVID-19 were associated with depression/anxiety, worse oral hygiene, and medication, all of which reinforce its multifactorial etiopathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.